Estramustine phosphate
Based on 1 publication(s) in Google Scholar
Estramustine phosphate, an estradiol analog, is an orally active antimicrotubule chemotherapy agent. Estramustine phosphate depolymerises microtubules by binding to microtubule associated proteins (MAPs) and/or to tubulin. Estramustine phosphate can interfere mitosis, trigger cell death and induce apoptosis, which can be used for the research of cancer like prostate cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 4891-15-0
- Fòrmula: C23H32Cl2NO6P
- Peso molecular:520.38
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Estramustine phosphate
More
Actividad biológica
Estramustine phosphate (1 µg/mL, 48 h) suppresses PC3 cell growth[1]. Estramustine phosphate (2 µg/mL, 48 h) elevates phosphatidylserine eversion amount on PC3 cells and induces PC3 cell apoptosis through reducing miR-31[1]. Estramustine phosphate (0-40 µM, 24-72 h) inhibits cell proliferation and tubulin cytoskeleton in RAW 264.7 cells[2]. Estramustine phosphate (10 µM, 24 h) inhibits TGF-β-induced RAW 264.7 cell migration, as well as TGF-β-induced uPA production by inhibiting Smad3 activation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PC3 cells
-
Concentration:1 µg/ mL
-
Incubation Time:48 h
-
Result:Suppressed PC3 cell growth.
-
Cell Line:RAW 264.7 cells
-
Concentration:10 µM
-
Incubation Time:24 h
-
Result:Disrupted the interphase microtubules.
-
Cell Line:18 h of TGF-β treated RAW 264.7 cells
-
Concentration:10 µM
-
Incubation Time:24 h
-
Result:Inhibited TGF-β-Induced Cell Migration.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Human prostate cancer xenograft PAC120[3]
-
Dosage:4 or 12 mg/kg, a daily dose for 2 weeks.
-
Administration:Intraperitoneal injection
-
Result:Inhibited PAC120 tumor growth 53% by day 35.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 4891-15-0
-
Peso molecular 520.38
-
Fòrmula C23H32Cl2NO6P
-
SMILES
O=C(OC1=CC=C2[C@@]3([H])CC[C@]4(C)[C@@H](OP(O)(O)=O)CC[C@@]4([H])[C@]3([H])CCC2=C1)N(CCCl)CCCl
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Pureza y Documentación
Referencias
[1]. C Wei, et al. Estramustine phosphate induces prostate cancer cell line PC3 apoptosis by down-regulating miR-31 levels. Eur Rev Med Pharmacol Sci. 2018 Jan;22(1):40-45. [Content Brief]
[2]. Sonja S Mojsilovic, et al. Estramustine Phosphate Inhibits TGF- β-Induced Mouse Macrophage Migration and Urokinase-Type Plasminogen Activator Production. Anal Cell Pathol (Amst). 2018 Sep 2;2018:3134102. [Content Brief]
[3]. Stephane Oudard, et al. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol. 2003 May;169(5):1729-34. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Estramustine phosphate Related Classifications
HY-13627A Related Classifications
Powered by Bioz